Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale (NASDAQ:BVS)
Bioventus benefits from improved financing flexibility, with a term loan maturity extended to 2030 and a 75 bps interest margin reduction. See why BVS is a Buy.
We can't find the internet
Attempting to reconnectSomething went wrong!
Attempting to reconnectBioventus benefits from improved financing flexibility, with a term loan maturity extended to 2030 and a 75 bps interest margin reduction. See why BVS is a Buy.